These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 25408217)
21. MRI-visible perivascular space location is associated with Alzheimer's disease independently of amyloid burden. Banerjee G; Kim HJ; Fox Z; Jäger HR; Wilson D; Charidimou A; Na HK; Na DL; Seo SW; Werring DJ Brain; 2017 Apr; 140(4):1107-1116. PubMed ID: 28335021 [TBL] [Abstract][Full Text] [Related]
22. Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's disease. Carmona-Iragui M; Balasa M; Benejam B; Alcolea D; Fernández S; Videla L; Sala I; Sánchez-Saudinós MB; Morenas-Rodriguez E; Ribosa-Nogué R; Illán-Gala I; Gonzalez-Ortiz S; Clarimón J; Schmitt F; Powell DK; Bosch B; Lladó A; Rafii MS; Head E; Molinuevo JL; Blesa R; Videla S; Lleó A; Sánchez-Valle R; Fortea J Alzheimers Dement; 2017 Nov; 13(11):1251-1260. PubMed ID: 28463681 [TBL] [Abstract][Full Text] [Related]
23. Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis. Arrighi HM; Barakos J; Barkhof F; Tampieri D; Jack C; Melançon D; Morris K; Ketter N; Liu E; Brashear HR J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):106-12. PubMed ID: 25669746 [TBL] [Abstract][Full Text] [Related]
24. Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients. Ketter N; Brashear HR; Bogert J; Di J; Miaux Y; Gass A; Purcell DD; Barkhof F; Arrighi HM J Alzheimers Dis; 2017; 57(2):557-573. PubMed ID: 28269765 [TBL] [Abstract][Full Text] [Related]
25. Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models. Liao F; Zhang TJ; Jiang H; Lefton KB; Robinson GO; Vassar R; Sullivan PM; Holtzman DM Acta Neuropathol Commun; 2015 Nov; 3():70. PubMed ID: 26556230 [TBL] [Abstract][Full Text] [Related]
26. ApoA1, ApoJ and ApoE Plasma Levels and Genotype Frequencies in Cerebral Amyloid Angiopathy. Montañola A; de Retana SF; López-Rueda A; Merino-Zamorano C; Penalba A; Fernández-Álvarez P; Rodríguez-Luna D; Malagelada A; Pujadas F; Montaner J; Hernández-Guillamon M Neuromolecular Med; 2016 Mar; 18(1):99-108. PubMed ID: 26661731 [TBL] [Abstract][Full Text] [Related]
27. Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer's Disease and Cerebral Amyloid Angiopathy. DiFrancesco JC; Longoni M; Piazza F Front Neurol; 2015; 6():207. PubMed ID: 26441825 [TBL] [Abstract][Full Text] [Related]
28. Course of cerebral amyloid angiopathy-related inflammation. Kinnecom C; Lev MH; Wendell L; Smith EE; Rosand J; Frosch MP; Greenberg SM Neurology; 2007 Apr; 68(17):1411-6. PubMed ID: 17452586 [TBL] [Abstract][Full Text] [Related]
33. Cerebral amyloid angiopathy is a pathogenic lesion in Alzheimer's disease due to a novel presenilin 1 mutation. Dermaut B; Kumar-Singh S; De Jonghe C; Cruts M; Löfgren A; Lübke U; Cras P; Dom R; De Deyn PP; Martin JJ; Van Broeckhoven C Brain; 2001 Dec; 124(Pt 12):2383-92. PubMed ID: 11701593 [TBL] [Abstract][Full Text] [Related]
34. Cerebral Amyloid Angiopathy-Related Inflammation Biomarkers: Where are we Now? Charidimou A J Alzheimers Dis; 2016; 50(1):9-11. PubMed ID: 26756457 [TBL] [Abstract][Full Text] [Related]
35. Association of Hypercholesterolemia with Alzheimer's Disease Pathology and Cerebral Amyloid Angiopathy. Xu C; Apostolova LG; Oblak AL; Gao S J Alzheimers Dis; 2020; 73(4):1305-1311. PubMed ID: 31929164 [TBL] [Abstract][Full Text] [Related]
36. Amyloid angiopathy in a Volga German family with Alzheimer's disease and a presenilin-2 mutation (N141I). Nochlin D; Bird TD; Nemens EJ; Ball MJ; Sumi SM Ann Neurol; 1998 Jan; 43(1):131-5. PubMed ID: 9450781 [TBL] [Abstract][Full Text] [Related]
37. Genetic associations between cathepsin D exon 2 C-->T polymorphism and Alzheimer's disease, and pathological correlations with genotype. Davidson Y; Gibbons L; Pritchard A; Hardicre J; Wren J; Tian J; Shi J; Stopford C; Julien C; Thompson J; Payton A; Thaker U; Hayes AJ; Iwatsubo T; Pickering-Brown SM; Pendleton N; Horan MA; Burns A; Purandare N; Lendon CL; Neary D; Snowden JS; Mann DM J Neurol Neurosurg Psychiatry; 2006 Apr; 77(4):515-7. PubMed ID: 16543533 [TBL] [Abstract][Full Text] [Related]
38. Capillary CAA and perivascular Aβ-deposition: two distinct features of Alzheimer's disease pathology. Attems J; Yamaguchi H; Saido TC; Thal DR J Neurol Sci; 2010 Dec; 299(1-2):155-62. PubMed ID: 20850138 [TBL] [Abstract][Full Text] [Related]
39. Data-driven models of dominantly-inherited Alzheimer's disease progression. Oxtoby NP; Young AL; Cash DM; Benzinger TLS; Fagan AM; Morris JC; Bateman RJ; Fox NC; Schott JM; Alexander DC Brain; 2018 May; 141(5):1529-1544. PubMed ID: 29579160 [TBL] [Abstract][Full Text] [Related]
40. Association between apolipoprotein E e4 allele and arteriosclerosis, cerebral amyloid angiopathy, and cerebral white matter damage in Alzheimer's disease. Tian J; Shi J; Bailey K; Lendon CL; Pickering-Brown SM; Mann DM J Neurol Neurosurg Psychiatry; 2004 May; 75(5):696-9. PubMed ID: 15090562 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]